While the Commission did not adopt any Article 102 prohibition decisions in 2012, commitment proceedings under Article 9 of Regulation 1/2003 and public statements by senior officials shed some light on its likely analytical approach and future enforcement priorities. The General Court and Court of Justice upheld prohibition decisions in several important judgments, including in AstraZeneca, which establishes a new category of abuse consisting in the exclusionary misuse of regulatory proceedings. The Courts' rulings are broadly consistent with previous case law and/or the analytical approach described in the Commission's Guidance Paper, enhancing legal certainty for stakeholders and national competition authorities.